Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
Gerald Posner, Pulitzer-nominated investigative journalist and veteran pharma watchdog, joins the Beyond Gender podcast to expose how profit motives and a silenced press enabled the rapid medicalisation of gender-questioning children. For British listeners, the argument is uncomfortably familiar: the same pharmaceutical incentives and institutional cowardice that Posner identifies in America also shaped the Tavistock pathway, and the Cass Review, for all its importance, addressed clinical evidence rather than the commercial machinery behind it.
Gerald Posner spent decades following pharmaceutical money before most journalists were willing to look. A Pulitzer Prize finalist and former attorney, he brings to the Beyond Gender podcast a methodological rigour that is rare in this debate. His starting point is not ideology but forensic financial analysis: who profits, who funds the research, and whose interests are served when a medical pathway becomes the default response to a child's distress. At the heart of this episode is what Posner describes as the pharma playbook — a set of tactics the industry has deployed repeatedly, from heroin marketed as a safe painkiller to opioids promoted as non-addictive. He identifies puberty blockers and cross-sex hormones as the latest iteration: drugs dispensed off-label to minors, whose long-term effects remain poorly understood, and whose commercial logic depends on creating patients who require medical management for life. The comparison to the opioid crisis is not rhetorical. Posner argues that the regulatory and journalistic failures that allowed that catastrophe to unfold are being repeated, with children as the new market. The episode's sharpest challenge is directed at journalism itself. Posner describes how publishers have gone quiet, how reporters who pursue these questions find their work buried or rejected, and how the financial entanglement of media organisations with pharmaceutical advertising has blunted editorial courage. In Britain, the picture is mixed. A handful of journalists pursued the Tavistock story for years before institutions were willing to act. But large parts of the broadcast media were far slower to engage critically, and some outlets actively marginalised those raising legitimate safeguarding concerns. Posner's account of American newsrooms will feel recognisable to anyone who watched the British press navigate this story. Posner draws particular attention to leaked WPATH emails, which he argues reveal the extent to which political considerations shaped what were presented as clinical guidelines. For British audiences, this matters directly. The NHS Gender Identity Development Service at the Tavistock followed WPATH standards of care as its benchmark, and those guidelines influenced the clinical pathway that the Cass Review later found to rest on weak and selectively presented evidence. If Posner is right that WPATH guidance was politically managed rather than independently derived, it reinforces one of the Cass Review's central findings: that ideology entered the evidence base at source. Britain is at a particular moment. The Tavistock has closed, NHS puberty blocker prescriptions for gender dysphoria have been paused, and the Cass Review has established a new standard for evidence-based care. But the commercial and ideological pressures Posner describes have not disappeared. Private clinics continue to operate, the campaign against the Cass recommendations persists, and the question of who funds that effort deserves the same forensic scrutiny Posner applies to American institutions. This episode is a reminder that the British story cannot be understood apart from the global pharmaceutical and media ecosystem that helped produce it.
